Area of research
Pathology and Forensic Medicine · Surgery
Research interest
Research focused on Genome-wide association study and Single-nucleotide polymorphism, with related work in Locus (genetics), Scleroderma (fungus), Immunology. Notable publications include 'Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis', 'Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis', and 'GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways'.
Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases
German‐Austrian guideline on screening for anal dysplasia and anal carcinoma in people living with HIV
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG
Immune checkpoint inhibitors for children with xeroderma pigmentosum and advanced cutaneous squamous cell carcinoma: A case presentation and brief review
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status
Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
<scp>EuroGuiderm</scp> guideline on lichen sclerosus—Treatment of lichen sclerosus
Characterization of Vascular Niche in Systemic Sclerosis by Spatial Proteomics
EuroGuiderm guideline on lichen sclerosus—introduction into lichen sclerosus
S2k guideline: Diagnosis and therapy of localized scleroderma
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma
Early versus late response to PD-1-based immunotherapy in metastatic melanoma
Cytokeratin 17 expression is commonly observed in keratinocytic skin tumours and controls tissue homeostasis impacting human papillomavirus protein expression
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas
Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective <scp>DeCOG</scp> registry <scp>ADOReg</scp>
S2k‐Leitlinie: Diagnostik und Therapie der zirkumskripten Sklerodermie
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
Characterisation and outcome of RAC1 mutated melanoma
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
1168P Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
S1 Guidelines for the Kaposi Sarcoma
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – An evaluation of the multicenter prospective skin cancer registry ADOREG
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors